Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $203.98 | 8 | 68.8% |
| Education | $92.29 | 3 | 31.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $129.35 | 5 | $0 (2024) |
| Veloxis Pharmaceuticals, Inc. | $81.88 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $60.52 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $24.52 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44.87 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($26.78) |
| 2023 | $164.02 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($69.58) |
| 2022 | $32.99 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($32.99) |
| 2019 | $54.39 | 1 | Veloxis Pharmaceuticals, Inc. ($54.39) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/13/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2023 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $19.81 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/17/2023 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: TRANSPLANTATION | ||||||
| 05/09/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: IMMUNOLOGY | ||||||
| 03/28/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.52 | General |
| 02/28/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2022 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2019 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug), Envarsus | Education | In-kind items and services | $54.39 | General |
| Category: Immunosuppressant | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 269 | 520 | $89,655 | $33,221 |
| 2022 | 8 | 386 | 810 | $144,461 | $50,963 |
| 2021 | 9 | 420 | 960 | $179,860 | $65,225 |
| 2020 | 9 | 466 | 1,077 | $205,958 | $70,758 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 192 | $26,688 | $11,312 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 71 | 100 | $20,900 | $6,634 | 31.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 38 | $14,896 | $4,888 | 32.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 45 | 49 | $13,720 | $4,820 | 35.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 28 | 65 | $4,940 | $2,456 | 49.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 23 | $4,623 | $2,119 | 45.8% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 12 | 12 | $2,904 | $656.52 | 22.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 17 | 41 | $984.00 | $336.59 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 79 | 281 | $39,059 | $15,209 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 107 | 171 | $35,739 | $10,905 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 99 | $27,720 | $10,761 | 38.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 43 | $16,856 | $6,667 | 39.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 54 | $10,854 | $4,019 | 37.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 19 | 34 | $8,228 | $1,850 | 22.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 17 | 19 | $3,379 | $1,237 | 36.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 24 | 109 | $2,626 | $313.97 | 12.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 151 | 311 | $65,543 | $22,252 | 34.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 89 | 373 | $51,847 | $21,236 | 41.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 62 | 70 | $27,440 | $11,041 | 40.2% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 29 | 56 | $13,552 | $3,130 | 23.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 30 | $6,030 | $2,409 | 40.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 20 | 25 | $4,444 | $1,859 | 41.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $5,187 | $1,610 | 31.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 15 | $4,200 | $1,487 | 35.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 19 | 67 | $1,618 | $201.00 | 12.4% |
About Dr. Charles Moritz, MD
Dr. Charles Moritz, MD is a Nephrology healthcare provider based in Temple, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851328124.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Moritz, MD has received a total of $296.27 in payments from pharmaceutical and medical device companies, with $44.87 received in 2024. These payments were reported across 11 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($203.98).
As a Medicare-enrolled provider, Moritz has provided services to 1,541 Medicare beneficiaries, totaling 3,367 services with total Medicare billing of $220,167. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Temple, TX
- Active Since 06/26/2006
- Last Updated 01/26/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1851328124
Products in Payments
- LIVTENCITY (Drug) $129.35
- Envarsus (Drug) $54.39
- PREVYMIS (Drug) $37.90
- ENVARSUS (Drug) $27.49
- DIFICID (Drug) $22.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Temple
Dr. Mohanram Narayanan, M.d, M.D
Nephrology — Payments: $141,091
Tony Issac, Md, MD
Nephrology — Payments: $1,169
Abraham Rajan, Md, MD
Nephrology — Payments: $937.48
Dr. Nimrit Goraya, M.d, M.D
Nephrology — Payments: $920.22
Dr. Nidhi Mattoo Munshi
Nephrology — Payments: $772.52
Dr. Luciana Mclean, M.d, M.D
Nephrology — Payments: $736.78